Aaron Ondrey
Finanzdirektor/CFO bei ROCKET PHARMACEUTICALS, INC.
Vermögen: 1 Mio $ am 30.04.2024
Profil
Aaron Ondrey is currently the Chief Financial Officer at Rocket Pharmaceuticals, Inc. He previously worked as the Executive Director-Commercial Finance at Regeneron Pharmaceuticals, Inc. from 2010 to 2018.
Additionally, he served as the Chief Financial Officer & SVP-Financial Planning at Mirati Therapeutics, Inc. from 2022 to 2024.
Mr. Ondrey obtained his undergraduate degree from Case Western Reserve University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.04.2024 | 46 781 ( 0,05% ) | 1 Mio $ | 30.04.2024 |
Aktive Positionen von Aaron Ondrey
| Unternehmen | Position | Beginn |
|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 26.03.2024 |
Ehemalige bekannte Positionen von Aaron Ondrey
| Unternehmen | Position | Ende |
|---|---|---|
| MIRATI THERAPEUTICS | Finanzdirektor/CFO | 23.01.2024 |
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.11.2018 |
Ausbildung von Aaron Ondrey
| Case Western Reserve University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
